Novartis AG stock (CH0012005267): Pharma giant eyes growth in weight-loss and cancer drugs

Novartis AG reports solid quarterly results and highlights progress in weight-loss and oncology pipelines, drawing attention from US investors.

Novartis AG posted first?quarter 2026 results that beat consensus expectations on revenue and adjusted earnings per share, as the Swiss pharmaceutical giant continues to lean on its oncology and cardiovascular franchises while advancing a pipeline of obesity and metabolic?disease candidates. The company reported net sales of 13.8 billion Swiss francs for the quarter, up about 10% at constant exchange rates, with core operating income rising roughly 12% year?on?year, according to Novartis investor relations as of May 9, 2026.

Management emphasized that growth was driven by strong demand for key oncology products such as Kisqali and Scemblix, as well as continued uptake of Entresto in heart?failure indications. The company also noted that its generics and biosimilars business, Sandoz, contributed positively to volume, even as pricing pressure in some markets moderated overall margin expansion. Novartis maintained its full?year 2026 guidance for mid?single?digit revenue growth at constant exchange rates and low?teens growth in core operating income, signaling confidence in its current portfolio and pipeline execution, according to Novartis investor relations as of May 9, 2026.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis AG
• Sector/industry: Pharmaceuticals and healthcare
• Headquarters/country: Basel, Switzerland
• Core markets: United States, Europe, Japan, and emerging markets
• Key revenue drivers: Oncology, cardiovascular, immunology, and generics/biosimilars
• Home exchange/listing venue: SIX Swiss Exchange (ticker: NOVN)
• Trading currency: Swiss francs

Novartis AG: core business model

Novartis AG operates as a global research?driven pharmaceutical company with a diversified portfolio spanning innovative medicines, generics and biosimilars, and eye?care products. The group’s business model centers on discovering, developing, and commercializing prescription drugs for chronic and complex diseases, including cancer, cardiovascular conditions, immunology disorders, and rare diseases. In addition, Novartis markets a broad range of generic and biosimilar medicines through its Sandoz division, which targets cost?sensitive healthcare systems and payers.

The company generates the majority of its revenue from patented innovative drugs, which typically carry higher margins and longer?term growth potential. These products are supported by global clinical development programs, regulatory submissions, and lifecycle management strategies such as label expansions and combination therapies. Sandoz, by contrast, focuses on price?competitive offerings in mature therapeutic areas, helping Novartis maintain volume and market share in markets where branded?drug exclusivity has expired.

For US investors, Novartis is relevant both as a large?cap international pharma holding and as a proxy for exposure to key US healthcare trends, including oncology innovation, managed?care pricing dynamics, and the shift toward value?based reimbursement. The company’s US operations contribute a significant share of group sales, and several of its flagship brands are marketed directly to US physicians and patients through local commercial teams.

Main revenue and product drivers for Novartis AG

Novartis’s revenue base is anchored in several high?growth therapeutic areas, with oncology and cardiovascular therapies representing the largest segments. In oncology, products such as Kisqali (ribociclib) for hormone?receptor?positive breast cancer and Scemblix (asciminib) for chronic myeloid leukemia continue to gain share in competitive markets. The company has also invested heavily in cell and gene therapies, including Kymriah, a CAR?T treatment for certain blood cancers, which remains a strategic growth platform despite manufacturing and reimbursement challenges.

Cardiovascular and metabolic franchises are another key pillar, led by Entresto, a heart?failure therapy that has expanded into earlier?stage indications and broader patient populations. Entresto’s uptake in the United States has been supported by favorable clinical trial data and inclusion in major treatment guidelines, helping Novartis capture a substantial portion of the heart?failure market. In addition, the company markets a range of hypertension and diabetes?related products that benefit from the growing prevalence of cardiometabolic disease in the US and other developed markets.

Immunology and dermatology products, including Cosentyx for psoriasis and related inflammatory conditions, contribute further to Novartis’s top line. The company is also advancing a pipeline of obesity and metabolic?disease candidates, positioning itself to participate in the rapidly expanding weight?loss drug market alongside peers such as Eli Lilly and Novo Nordisk. These pipeline assets, if successfully developed and approved, could become meaningful revenue drivers over the next several years.

Conclusion

Novartis AG’s latest quarterly performance underscores the resilience of its core oncology and cardiovascular franchises, while its pipeline in obesity and metabolic diseases offers potential upside for long?term investors. The company’s diversified business model, spanning innovative medicines and generics, provides a degree of revenue stability even as pricing and regulatory pressures persist in key markets such as the United States. At the same time, Novartis faces ongoing challenges related to patent expirations, competition from rival pharma players, and the need to continuously replenish its pipeline with successful new drug launches.

For US investors, Novartis represents a large?cap international exposure to global healthcare innovation, with particular relevance to oncology, cardiovascular care, and the emerging weight?loss drug segment. The stock’s valuation and dividend profile may appeal to income?oriented and growth?oriented investors alike, though the inherent risks of clinical development, regulatory decisions, and pricing negotiations should be carefully weighed. As with any equity investment, prospective shareholders should consider their risk tolerance, time horizon, and portfolio diversification before making decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.